Published in J Exp Med on October 01, 1992
Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection. J Exp Med (1993) 3.29
Rev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotes. Mol Cell Biol (1993) 2.79
Retracted Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci U S A (1994) 2.30
The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol (1997) 1.78
Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci U S A (1997) 1.53
Evidence for specific nucleocytoplasmic transport pathways used by leucine-rich nuclear export signals. Proc Natl Acad Sci U S A (1999) 1.49
Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J Virol (1993) 1.36
Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci U S A (1996) 1.30
A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle. J Virol (2009) 1.30
A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci U S A (1996) 1.27
RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J Virol (1997) 1.23
Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J Virol (1994) 1.22
RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo. J Virol (1996) 1.22
Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A (1998) 1.17
Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc Natl Acad Sci U S A (1994) 1.12
CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology (2005) 1.10
Functional analysis of the human immunodeficiency virus type 1 Rev protein oligomerization interface. J Virol (1998) 1.10
Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med (2012) 1.07
Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy. J Virol (1996) 1.06
HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther (2005) 1.05
Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci U S A (1995) 1.00
Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis. Retrovirology (2015) 1.00
HIV/AIDS eradication. Bioorg Med Chem Lett (2013) 0.98
Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73. J Virol (2000) 0.97
Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol (1995) 0.95
Selection and characterization of human immunodeficiency virus type 1 mutants that are resistant to inhibition by the transdominant negative RevM10 protein. J Virol (1999) 0.94
Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci U S A (1997) 0.92
Gene therapy for infectious diseases. Clin Microbiol Rev (1998) 0.91
Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein. J Virol (1996) 0.90
Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins. J Virol (1998) 0.88
A nuclear export signal within the structural Gag protein is required for prototype foamy virus replication. Retrovirology (2011) 0.86
Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins. J Virol (1996) 0.86
Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J Virol (1998) 0.86
Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (2008) 0.85
Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication. Nucleic Acids Res (1998) 0.83
Use of a human immunodeficiency virus type 1 Rev mutant without nucleolar dysfunction as a candidate for potential AIDS therapy. J Virol (1995) 0.82
Suppression of simian immunodeficiency virus replication by human immunodeficiency virus type 1 trans-dominant negative rev mutants. J Virol (1995) 0.82
A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells. Hum Gene Ther (2013) 0.82
Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther (2015) 0.81
Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes. J Virol (1996) 0.81
Opioid-induced chemokine expression requires NF-κB activity: the role of PKCζ. J Leukoc Biol (2010) 0.80
Bone Marrow Gene Therapy for HIV/AIDS. Viruses (2015) 0.79
Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion host shutoff protein. J Virol (1997) 0.78
Gene therapy for HIV infections: Intracellular immunization. Can J Infect Dis (1999) 0.77
New approach for inhibiting Rev function and HIV-1 production using the influenza virus NS1 protein. Proc Natl Acad Sci U S A (1996) 0.77
Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene. J Virol (1997) 0.75
VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication. World J Gastroenterol (2005) 0.75
A reporter based single step assay for evaluation of inhibitors targeting HIV-1 Rev-RRE interaction. Virusdisease (2013) 0.75
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 19.23
The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature (1989) 13.92
Functional inactivation of genes by dominant negative mutations. Nature (1987) 13.12
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol (1989) 9.37
Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A (1988) 9.35
rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc Natl Acad Sci U S A (1989) 8.76
Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A (1987) 7.91
Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function. Cell (1989) 7.46
Regulation by HIV Rev depends upon recognition of splice sites. Cell (1989) 7.13
Regulation of human immunodeficiency virus env expression by the rev gene product. J Virol (1989) 5.79
Expression of human class II major histocompatibility complex antigens using retrovirus vectors. Proc Natl Acad Sci U S A (1987) 4.84
Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell (1990) 4.78
HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell (1991) 4.61
Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells. Science (1988) 4.16
Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J Virol (1991) 3.94
Gene therapy. Intracellular immunization. Nature (1988) 3.60
Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell (1990) 3.36
Quantitative infectivity assay for HIV-1 and-2. Nature (1988) 3.01
U1 small nuclear RNA plays a direct role in the formation of a rev-regulated human immunodeficiency virus env mRNA that remains unspliced. Proc Natl Acad Sci U S A (1990) 2.90
Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids. Genes Dev (1990) 2.87
Identification of trans-dominant HIV-1 rev protein mutants by direct transfer of bacterially produced proteins into human cells. Nucleic Acids Res (1990) 2.14
Specific complex of human immunodeficiency virus type 1 rev and nucleolar B23 proteins: dissociation by the Rev response element. Mol Cell Biol (1991) 2.02
Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetyltransferase enzyme. Proc Natl Acad Sci U S A (1989) 1.96
Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science (1989) 1.95
Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc Natl Acad Sci U S A (1989) 1.78
Mutants in a conserved region near the carboxy-terminus of HIV-1 Rev identify functionally important residues and exhibit a dominant negative phenotype. Virology (1990) 1.48
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature (1989) 13.92
Use of eukaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol (1987) 12.66
Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A (1989) 11.76
Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell (1986) 10.71
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (1991) 10.53
Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 8.32
fw2.2: a quantitative trait locus key to the evolution of tomato fruit size. Science (2000) 7.91
Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function. Cell (1989) 7.46
HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature (1988) 7.35
A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 6.82
Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 6.36
Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature (1988) 6.28
Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene (1988) 6.13
Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 6.02
Digital tomosynthesis in breast imaging. Radiology (1997) 5.82
HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell (1990) 5.82
Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A (1997) 5.76
Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature (1989) 5.76
Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med (2001) 5.68
Transcriptional interference in avian retroviruses--implications for the promoter insertion model of leukaemogenesis. Nature (1984) 5.26
Separation of caveolae from associated microdomains of GPI-anchored proteins. Science (1995) 5.25
Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65. Nature (1991) 5.07
High fertilization and implantation rates after intracytoplasmic sperm injection. Hum Reprod (1993) 5.06
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events. Proc Natl Acad Sci U S A (1987) 4.91
Comparing sequenced segments of the tomato and Arabidopsis genomes: large-scale duplication followed by selective gene loss creates a network of synteny. Proc Natl Acad Sci U S A (2000) 4.90
p53 inhibition by the LANA protein of KSHV protects against cell death. Nature (2000) 4.74
HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell (1991) 4.61
Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med (1991) 4.56
Genome sequence, comparative analysis, and population genetics of the domestic horse. Science (2009) 4.41
Activation of Arp2/3 complex-mediated actin polymerization by cortactin. Nat Cell Biol (2001) 4.38
Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science (1997) 4.37
Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med (2000) 4.36
Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science (1986) 4.30
Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science (1998) 4.24
Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay. Mol Cell Biol (1996) 4.10
Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl (1996) 3.99
Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J Virol (1991) 3.94
Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma. N Engl J Med (1997) 3.90
Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci U S A (1996) 3.83
Ultralong single-wall carbon nanotubes. Nat Mater (2004) 3.83
A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J (1993) 3.74
Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat. J Virol (1988) 3.69
Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins. Cell (1995) 3.55
Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A (1987) 3.47
A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia (2007) 3.45
Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. Proc Natl Acad Sci U S A (1989) 3.43
Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature (1988) 3.31
Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int (2016) 3.30
Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection. J Exp Med (1993) 3.29
Developing a prediction rule from automated clinical databases to identify high-risk patients in a large population with diabetes. Diabetes Care (2001) 3.27
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (1989) 3.27
Immunization for Ebola virus infection. Nat Med (1998) 3.27
Genetic analysis of salt tolerance in arabidopsis. Evidence for a critical role of potassium nutrition. Plant Cell (1998) 3.25
The human Tap protein is a nuclear mRNA export factor that contains novel RNA-binding and nucleocytoplasmic transport sequences. Genes Dev (1999) 3.24
The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science (1999) 3.23
The major facilitator superfamily. J Mol Microbiol Biotechnol (1999) 3.17
Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med (2001) 3.11
Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. Genes Dev (1989) 3.09
Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J (1998) 3.05
Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care (1997) 3.03
Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem (1996) 3.01
A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors. Nature (1987) 3.00
Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol (1998) 2.99
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res Hum Retroviruses (1988) 2.99
Acupuncture modulates the limbic system and subcortical gray structures of the human brain: evidence from fMRI studies in normal subjects. Hum Brain Mapp (2000) 2.98
Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol (1999) 2.95
Genetic architecture of a morphological shape difference between two Drosophila species. Genetics (2000) 2.92
New tumor markers: CA125 and beyond. Int J Gynecol Cancer (2005) 2.92
SOS3 function in plant salt tolerance requires N-myristoylation and calcium binding. Plant Cell (2000) 2.91
The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals. Mol Cell Biol (1999) 2.90
Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol (1989) 2.89
Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol (1995) 2.88
Essential function of Gli2 and Gli3 in the formation of lung, trachea and oesophagus. Nat Genet (1998) 2.87
HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J (1997) 2.86
Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev (2001) 2.84
Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene (2012) 2.82
Rev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotes. Mol Cell Biol (1993) 2.79
Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science (1994) 2.79
Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP. Nat Genet (2001) 2.75
Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J Virol (2000) 2.72
Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci U S A (1992) 2.72
Toxicity of ALS-linked SOD1 mutants. Science (2000) 2.69
Survival of recipients of livers from donation after circulatory death who are relisted and undergo retransplant for graft failure. Am J Transplant (2014) 2.67
Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science (1990) 2.63
Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. J Virol (1991) 2.62
Nuclear import of hnRNP A1 is mediated by a novel cellular cofactor related to karyopherin-beta. J Cell Sci (1997) 2.60
A cloned MCGF cDNA encodes a multilineage hematopoietic growth factor: multiple activities of interleukin 3. J Immunol (1985) 2.56
Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part i: morbidity and mortality monitoring. Circulation (2001) 2.56
cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1. Mol Cell Biol (1992) 2.55
Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol (1993) 2.54
Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A (1987) 2.53
Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein. Curr Biol (1999) 2.52
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 2.49
Intracytoplasmic single sperm injection of 1-day-old unfertilized human oocytes. Hum Reprod (1993) 2.46
Regulation of the proinflammatory effects of Fas ligand (CD95L). Science (1998) 2.43
Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases. J Biol Chem (1995) 2.41